Kathrin Meyer

Title: Kathrin Meyer: Innovator in Gene Therapy

Introduction

Kathrin Meyer is a prominent inventor based in Columbus, OH (US). She has made significant contributions to the field of gene therapy, particularly in the treatment of neuronal ceroid lipofuscinosis, also known as CLN3-Batten Disease. Her innovative work focuses on the delivery of therapeutic agents using recombinant adeno-associated virus (rAAV) technology.

Latest Patents

Kathrin Meyer holds a patent titled "Adeno-associated virus delivery of CLN3 polynucleotide." This patent relates to the use of rAAV for the delivery of a CLN3 polynucleotide, which is crucial for gene therapy aimed at treating CLN3-Batten Disease. Her work in this area is groundbreaking and has the potential to improve the lives of those affected by this condition. She has 1 patent to her name.

Career Highlights

Throughout her career, Kathrin has worked with esteemed organizations such as the Research Institute at Nationwide Children's Hospital and the Ohio State Innovation Foundation. Her dedication to advancing medical science through innovative research has established her as a key figure in her field.

Collaborations

Kathrin has collaborated with notable professionals, including Brian K. Kaspar and Kevin Foust. These partnerships have further enhanced her research and contributed to the development of effective gene therapies.

Conclusion

Kathrin Meyer is a trailblazer in the field of gene therapy, with her innovative approaches to treating CLN3-Batten Disease showcasing her commitment to improving patient outcomes. Her contributions to science and medicine are invaluable and continue to inspire future research in the field.